MedPath

Inj. Ferric Carboxymaltose (FCM) Vs Iron Isomaltoside (IIM) in treatment of iron deficiency anemia in Pregnancy (Antenatal)

Not Applicable
Completed
Conditions
Health Condition 1: O20-O29- Other maternal disorders predominantly related to pregnancy
Registration Number
CTRI/2020/05/025180
Lead Sponsor
Bhawna Garg
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
140
Inclusion Criteria

Antepartum women whose Hemoglobin is in range of 7 to 10.9 gram per decilitre

Women in second trimester of pregnancy (14- to 22 weeks)

Exclusion Criteria

Women not willing to participate

Women with less than 14 weeks of gestation

Women in labor

Known case of Thalassemia or Megaloblastic anemia

Women who have a history or known allergy to parenteral iron infusion.

Women with normal serum ferritin levels

history of any liver disease

history of any Autoimmune disease

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath